SELLAS Life Sciences Gr Analyst Price Targets

Wall Street analyst price targets and consensus rating for SELLAS Life Sciences Gr (SLS).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOverweight# Analysts2Avg. Consensus PT$7Upside to Avg. PT-32.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 12, 2026	Maxim Group	Jason McCarthy	PT Raise	Buy	$7→$10
Jul 16, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$4→$7
Nov 22, 2023	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	$3

Analyst Ratings News

PRO
Maxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and raises the price target from $4 to $7.

Benzinga Newsdesk

Galena Biopharma Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

Zacks

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.

Benzinga Newsdesk

PRO
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

Alliance Global Partners analyst James Molloy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and lowers the price target from $14 to $8.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

Cantor Fitzgerald analyst Li Watsek maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and lowers the price target from $10 to $6.

Benzinga Newsdesk

SELLAS Life Sciences Group Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

SELLAS Life Sciences Gr Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

Galena Biopharma Upgraded to Buy: Here's What You Should Know

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

PRO
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

PRO
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

People Also Watch

People Also Watch

SELLAS Life Sciences Group Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

SELLAS Life Sciences Gr Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

Galena Biopharma Upgraded to Buy: Here's What You Should Know

PROCantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

PROCantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

PROAlliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

PROCantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

People Also Watch

People Also Watch

PRO
Maxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

PRO
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

PRO
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6